|
1
|
Ferlay J, Shin HR, Bray F, Forman D,
Mathers C and Parkin DM: Estimates of worldwide burden of cancer in
2008: GLOBOCAN 2008. Int J Cancer. 127:2893–2917. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Aljiffry M, Abdulelah A, Walsh M,
Peltekian K, Alwayn I and Molinari M: Evidence-based approach to
cholangiocarcinoma: A systematic review of the current literature.
J Am Coll Surg. 208:134–147. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Parkin DM, Ohshima H, Srivatanakul P and
Vatanasapt V: Cholangiocarcinoma: Epidemiology, mechanisms of
carcinogenesis and prevention. Cancer Epidemiol Biomarkers Prev.
2:537–544. 1993.PubMed/NCBI
|
|
4
|
Mosadeghi S, Liu B, Bhuket T and Wong RJ:
Sex-specific and race/ethnicity-specific disparities in
cholangiocarcinoma incidence and prevalence in the USA: An updated
analysis of the 2000–2011 surveillance, epidemiology and end
results registry. Hepatol Res. 46:669–677. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Butthongkomvong K, Sirachainan E,
Jhankumpha S, Kumdang S and Sukhontharot OU: Treatment outcome of
palliative chemotherapy in inoperable cholangiocarcinoma in
Thailand. Asian Pac J Cancer Prev. 14:3565–3568. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Smout MJ, Sotillo J, Laha T, Papatpremsiri
A, Rinaldi G, Pimenta RN, Chan LY, Johnson MS, Turnbull L,
Whitchurch CB, et al: Carcinogenic parasite secretes growth factor
that accelerates wound healing and potentially promotes neoplasia.
PLoS Pathog. 11:e10052092015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Friman S: Cholangiocarcinoma-current
treatment options. Scand J Surg. 100:30–34. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Murakami Y, Uemura K, Sudo T, Hashimoto Y,
Nakashima A, Kondo N, Sakabe R, Ohge H and Sueda T: Prognostic
factors after surgical resection for intrahepatic, hilar, and
distal cholangiocarcinoma. Ann Surg Oncol. 18:651–658. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Patel T: Cholangiocarcinoma-controversies
and challenges. Nat Rev Gastroenterol Hepatol. 8:189–200. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Andersen JB and Thorgeirsson SS: Genetic
profiling of intrahepatic cholangiocarcinoma. Curr Opin
Gastroenterol. 28:266–272. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
McAlpine JA, Lu HT, Wu KC, Knowles SK and
Thomson JA: Down-regulation of argininosuccinate synthetase is
associated with cisplatin resistance in hepatocellular carcinoma
cell lines: Implications for PEGylated arginine deiminase
combination therapy. BMC Cancer. 14:6212014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Bowles TL, Kim R, Galante J, Parsons CM,
Virudachalam S, Kung HJ and Bold RJ: Pancreatic cancer cell lines
deficient in argininosuccinate synthetase are sensitive to arginine
deprivation by arginine deiminase. Int J Cancer. 123:1950–1955.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Delage B, Fennell DA, Nicholson L, McNeish
I, Lemoine NR, Crook T and Szlosarek PW: Arginine deprivation and
argininosuccinate synthetase expression in the treatment of cancer.
Int J Cancer. 126:2762–2772. 2010.PubMed/NCBI
|
|
14
|
Savaraj N, Wu C, Kuo MT, You M,
Wangpaichitr M, Robles C, Spector S and Feun L: The relationship of
arginine deprivation, argininosuccinate synthetase and cell death
in melanoma. Drug Target Insights. 2:119–128. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Savaraj N, You M, Wu C, Wangpaichitr M,
Kuo MT and Feun LG: Arginine deprivation, autophagy, apoptosis
(AAA) for the treatment of melanoma. Curr Mol Med. 10:405–412.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Phillips MM, Sheaff MT and Szlosarek PW:
Targeting arginine-dependent cancers with arginine-degrading
enzymes: Opportunities and challenges. Cancer Res Treat.
45:251–262. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Hahnvajanawong C, Chaiyagool J, Seubwai W,
Bhudhisawasdi V, Namwat N, Khuntikeo N, Sripa B, Pugkhem A and
Tassaneeyakul W: Orotate phosphoribosyl transferase mRNA expression
and the response of cholangiocarcinoma to 5-fluorouracil. World J
Gastroenterol. 18:3955–3961. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Rattanasinganchan P, Leelawat K,
Treepongkaruna SA, Tocharoentanaphol C, Subwongcharoen S,
Suthiphongchai T and Tohtong R: Establishment and characterization
of a cholangiocarcinoma cell line (RMCCA-1) from a Thai patient.
World J Gastroenterol. 12:6500–6506. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Sirisinha S, Tengchaisri T, Boonpucknavig
S, Prempracha N, Ratanarapee S and Pausawasdi A: Establishment and
characterization of a cholangiocarcinoma cell line from a Thai
patient with intrahepatic bile duct cancer. Asian Pac J Allergy
Immunol. 9:153–157. 1991.PubMed/NCBI
|
|
20
|
Savaraj N, Wu C, Li YY, Wangpaichitr M,
You M, Bomalaski J, He W, Kuo MT and Feun LG: Targeting
argininosuccinate synthetase negative melanomas using combination
of arginine degrading enzyme and cisplatin. Oncotarget.
6:6295–6309. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Thongkum A, Wu C, Li YY, Wangpaichitr M,
Navasumrit P, Parnlob V, Sricharunrat T, Bhudhisawasdi V,
Ruchirawat M and Savaraj N: The combination of arginine deprivation
and 5-fluorouracil improves therapeutic efficacy in
argininosuccinate synthetase negative hepatocellular carcinoma. Int
J Mol Sci. 18(pii): E11752017. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Beddowes E, Spicer J, Chan PY, Khadeir R,
Corbacho JG, Repana D, Steele JP, Schmid P, Szyszko T, Cook G, et
al: Phase 1 dose-escalation study of pegylated arginine deiminase,
cisplatin, and pemetrexed in patients with argininosuccinate
synthetase 1-deficient thoracic cancers. J Clin Oncol.
35:1778–1785. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Locke M, Ghazaly E, Freitas MO, Mitsinga
M, Lattanzio L, Lo Nigro C, Nagano A, Wang J, Chelala C, Szlosarek
P and Martin SA: Inhibition of the polyamine synthesis pathway is
synthetically lethal with loss of argininosuccinate synthase 1.
Cell Rep. 16:1604–1613. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Long Y, Tsai WB, Wangpaichitr M, Tsukamoto
T, Savaraj N, Feun LG and Kuo MT: Arginine deiminase resistance in
melanoma cells is associated with metabolic reprogramming, glucose
dependence, and glutamine addiction. Mol Cancer Ther. 12:2581–2590.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Tsai WB, Aiba I, Long Y, Lin HK, Feun L,
Savaraj N and Kuo MT: Activation of Ras/PI3K/ERK pathway induces
c-Myc stabilization to upregulate argininosuccinate synthetase,
leading to arginine deiminase resistance in melanoma cells. Cancer
Res. 72:2622–2633. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Liu J, Ma J, Wu Z, Li W, Zhang D, Han L,
Wang F, Reindl KM, Wu E and Ma Q: Arginine deiminase augments the
chemosensitivity of argininosuccinate synthetase-deficient
pancreatic cancer cells to gemcitabine via inhibition of NF-κB
signaling. BMC Cancer. 14:6862014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Walts AE, Bomalaski JS, Ines D and Orsulic
S: Argininosuccinate synthetase (ASS) deficiency in high-grade
pulmonary neuroendocrine carcinoma: An opportunity for personalized
targeted therapy. J Cancer Res Clin Oncol. 141:1363–1369. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Horie S, Endo K, Kawasaki H and Terada T:
Overexpression of MDM2 protein in intrahepatic cholangiocarcinoma:
Relationship with p53 overexpression, Ki-67 labeling, and
clinicopathological features. Virchows Arch. 437:25–30. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Zhao W, Zhang B, Guo X, Zhang X, Hu J, Hu
X and Lu Y: Expression of Ki-67, Bax and p73 in patients with hilar
cholangiocarcinoma. Cancer Biomark. 14:197–202. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Iguchi T, Yamashita N, Aishima S, Kuroda
Y, Terashi T, Sugimachi K, Taguchi K, Taketomi A, Maehara Y and
Tsuneyoshi M: A comprehensive analysis of immunohistochemical
studies in intrahepatic cholangiocarcinoma using the survival tree
model. Oncology. 76:293–300. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Schiffman SC, Nowacki MR, Spencer L,
McMasters KM, Scoggins CR and Martin RC: Molecular factors
associated with recurrence and survival following hepatectomy in
patients with intrahepatic cholangiocarcinoma: A guide to adjuvant
clinical trials. J Surg Oncol. 109:98–103. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Tan GS, Lim KH, Tan HT, Khoo ML, Tan SH,
Toh HC and Ching Ming Chung M: Novel proteomic biomarker panel for
prediction of aggressive metastatic hepatocellular carcinoma
relapse in surgically resectable patients. J Proteome Res.
13:4833–4846. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Yang H, Lin M, Xiong FX, Yang Y, Nie X and
Zhou RL: Reduced expression of ASS is closely related to
clinicopathological features and post-resectional survival of
hepatocellular carcinoma. Oncol Lett. 1:31–36. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Yoon CY, Shim YJ, Kim EH, Lee JH, Won NH,
Kim JH, Park IS, Yoon DK and Min BH: Renal cell carcinoma does not
express argininosuccinate synthetase and is highly sensitive to
arginine deprivation via arginine deiminase. Int J Cancer.
120:897–905. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
You M, Savaraj N, Wangpaichitr M, Wu C,
Kuo MT, Varona-Santos J, Nguyen DM and Feun L: The combination of
ADI-PEG20 and TRAIL effectively increases cell death in melanoma
cell lines. Biochem Biophys Res Commun. 394:760–766. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Feun L, You M, Wu CJ, Kuo MT, Wangpaichitr
M, Spector S and Savaraj N: Arginine deprivation as a targeted
therapy for cancer. Curr Pharm Des. 14:1049–1057. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Wangpaichitr M, Wu C, Bigford G,
Theodoropoulos G, You M, Li YY, Verona-Santos J, Feun LG, Nguyen DM
and Savaraj N: Combination of arginine deprivation with TRAIL
treatment as a targeted-therapy for mesothelioma. Anticancer Res.
34:6991–6999. 2014.PubMed/NCBI
|
